NovoCure Ltd — Form 8-K
Filed July 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
NovoCure reported Q2 2026 net revenues of $183.6M (up 16% from $158.8M in Q2 2025), driven by 18% global active patient growth to 5,128 total patients. The company raised full-year 2026 net revenue guidance to $710M–$725M (prior: $690M–$710M) and adjusted EBITDA guidance to $0M–$15M (prior: $(15)M–$0M), reflecting improved profitability trajectory. Key developments: Optune Pax received EU CE Mark for locally advanced pancreatic cancer in June 2026 with 285 active patients in the U.S.; Optune Lua grew 51% YoY to 207 patients. Gross margin improved to 78% (from 74% prior year).
Why this rating
Revenue growth 16% YoY and guidance raise are solid but modest for a ~$1B company. Adjusted EBITDA swing from negative to breakeven/positive is meaningful. New Pax indication and patient growth are encouraging, but absolute patient numbers and new product revenue remain small. Not transformational but demonstrates operational progress.
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.